Neoadjuvant reaction for patients with operable HER2-positive breast cancer comparing trastuzumab + lapatinib

eagle-i ID

Resource Type

Properties

1. Intervention

   Trastuzumab

2. Intervention

   Lapatinib

3. Additional Topic(s)

   Adjuvant chemotherapy

4. Resource Description

   The primary aims of this study are to determine whether the regimen of AC → weekly paclitaxel (WP) plus trastuzumab plus lapatinib yields a greater rate of pCR than the regimen of AC → WP plus trastuzumab and to determine whether the regimen of AC → WP plus lapatinib yields a greater rate of pCR than the regimen of AC → WP plus trastuzumab.

5. Contact

   Berenberg, Jeffrey

6. PI

   Berenberg, Jeffrey

7. Topic

   breast cancer

8. Funded by

   National Surgical Adjuvant Breast and Bowel Project

9. Phase

   Phase 3 clinical trial

10. Performed by

    Clinical Protocol & Data Management Shared Resource